Trial reportBritish journal of clinical pharmacology1994
Inhibition of bradykinin-induced vasodilation in human forearm vasculature by icatibant, a potent B2-receptor antagonist.
Trial report in British journal of clinical pharmacology, 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 92 citations in OpenAlex.
- Modest Contribution of Bradykinin to Blood Pressure Reduction by Sacubitril/Valsartan in Chronic Heart Failure.Circulation. Heart failure · 2026Trial
- Bradykinin BBMC nephrology · 2023Trial
- Vasomotor and fibrinolytic responses to kinin receptor agonists in the atherosclerotic human lower limb.Heart and vessels · 2012Trial
- Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema.The New England journal of medicine · 2010Trial
- Endogenous bradykinin contributes to increased plasminogen activator inhibitor 1 antigen following hemodialysis.Journal of the American Society of Nephrology : JASN · 2009Trial
- Role of blood flow in regulating insulin-stimulated glucose uptake in humans. Studies using bradykinin, [15O]water, and [18F]fluoro-deoxy-glucose and positron emission tomography.The Journal of clinical investigation · 1996Trial
- Hantavirus: an overview and advancements in therapeutic approaches for infection.Frontiers in microbiology · 2023Review
- Therapeutic Polypeptides and Peptidomimetics: Powerful Tools for COVID-19 Treatment.Clinical drug investigation · 2023Review
- Treatment of hereditary angioedema-single or multiple pathways to the rescue.Frontiers in allergy · 2022Review
- Bradykinin Exerts Independent Effects on Trophoblast Invasion and Blood Pressure in Pregnant Guinea Pigs.Reproductive sciences (Thousand Oaks, Calif.) · 2020Article
- Angiotensin converting enzyme defects in shock: implications for future therapy.Critical care (London, England) · 2018Article
- The Story of Angioedema: from Quincke to Bradykinin.Clinical reviews in allergy & immunology · 2016Review
- Role of the bradykinin B2 receptor in a rat model of local heart irradiation.International journal of radiation biology · 2015Article
- Administration of angiotensin II and a bradykinin B2 receptor blocker in midpregnancy impairs gestational outcome in guinea pigs.Reproductive biology and endocrinology : RB&E · 2014Article
- Differences in vascular nitric oxide and endothelium-derived hyperpolarizing factor bioavailability in blacks and whites.Arteriosclerosis, thrombosis, and vascular biology · 2014Article
- ACE inhibition enhances bradykinin relaxations through nitric oxide and B1 receptor activation in bovine coronary arteries.Biological chemistry · 2013Article
- The effect of bradykinin B2 receptor polymorphisms on the susceptibility and severity of osteoarthritis in a Chinese cohort.Journal of biomedicine & biotechnology · 2012Article
- Therapeutic approaches in hereditary angioedema.Clinical reviews in allergy & immunology · 2011Review
- Icatibant.Drugs · 2010Article
- Effects of bradykinin on venous capacitance in health and treated chronic heart failure.Clinical science (London, England : 1979) · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
1. The effect of icatibant (D-Arg-[Hyp3, Thi5, D-Tic7, Oic8] bradykinin) a potent B2-kinin receptor antagonist, was studied on bradykinin-induced vasodilation in the human forearm. 2. Eight healthy normotensive men were studied in a rising dose random-placebo controlled study. Placebo and icatibant (20, 50 and 100 micrograms kg-1 i.v.) were administered double-blind. Forearm blood flow was measured by venous occlusion plethysmography during rising dose brachial artery infusions of bradykinin (10-3,000 ng min-1) 60-90 min after placebo or icatibant. 3. Plasma concentrations of icatibant fell exponentially following each of three doses, up to the final measurement. Elimination half-lives calculated from linear regression of the mean data were 25, 27 and 29 min after 20, 50 and 100 micrograms kg-1 doses respectively. 4. Icatibant inhibited the effect of bradykinin (P < 0.001 at each dose of icatibant) in a dose-dependent manner. Bradykinin (100 ng min-1) increased mean blood flow in the infused arm by 238 +/- 31% when infused following placebo, by 112 +/- 21% after icatibant 20 micrograms kg-1, by 71 +/- 14% after icatibant 50 micrograms kg-1 and by 48 +/- 9% after icatibant 100 micrograms kg-1. 5. These results demonstrate that icatibant antagonises B2-receptor mediated vasodilation in human forearm resistance vessels. The findings provide a quantitative basis for future studies of the role of bradykinin in the response to angiotensin converting enzyme inhibitors and in circulatory disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.